Brief: Alterity Therapeutics Announces U.S. FDA Approval For IND Application For ATH434 For MSA
20/09/2022 02:21
Sept 20 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* U.S. FDA APPROVAL FOR IND APPLICATION FOR ATH434 FOR MSA
Source text for Eikon: ID:nASX5pH2vj
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital